Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)  

The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern.

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine  

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.

t1

Test Study 2

Test Study 2

Study with site having site user

Study with site having site user

Test existing 2

Test Study on website

Test Study on website

Arthritis  

This Study is about Arthritis.

Campaign  

Campaign

Test Reports

Test Reports